The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension.
about
Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analysesTreatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertensionQuality of life in patients with chronic thromboembolic pulmonary hypertensionDevelopment of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH.Adaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands.The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocolExercise training in patients with pulmonary arterial hypertension: a case reportSubcutaneous treprostinil is well tolerated with infrequent site changes and analgesicsShort term effects of exercise training on exercise capacity and quality of life in patients with pulmonary arterial hypertension: protocol for a randomised controlled trial.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertensionAssessment of daily life physical activities in pulmonary arterial hypertension.Quality of life as a prognostic marker in pulmonary arterial hypertensionSublingual microcirculation in pulmonary arterial hypertension.Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional surveyThe development of patient-reported outcome indices for multiple sclerosis (PRIMUS).Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertensionAre transcutaneous oxygen and carbon dioxide determinations of value in pulmonary arterial hypertension?Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial HypertensionPatient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension.Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension.Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.An assessment of the effects of Iyengar yoga practice on the health-related quality of life of patients with chronic respiratory diseases: a pilot studyApplying Rasch analysis to evaluate measurement equivalence of different administration formats of the Activity Limitation scale of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension.Updating clinical endpoint definitions.Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.Greek adaptation and validation of the Ankylosing Spondylitis Quality of Life (ASQoL) measureAdaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-CanadianPsychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension.Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaireHealth-related quality of life and patient-reported outcomes in pulmonary arterial hypertension.Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients.Randomised controlled trial examining the effect of an outpatient exercise training programme on haemodynamics and cardiac MR parameters of right ventricular function in patients with pulmonary arterial hypertension: the ExPAH study protocol.emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension.A review of the management of pulmonary arterial hypertension associated with congenital heart disease.
P2860
Q21245613-FD422E16-09AA-4335-86F7-4F1EF8981DAFQ24598400-8058D8D1-B012-46F7-B751-1E1D4B8C7832Q26748611-BCC21AB4-0284-46C1-AA6A-DBA4D47BB677Q27304673-4301727E-EA3D-4C1F-A692-63E7D154AB9DQ27342609-E49A45ED-AC1F-4700-8A89-5BD9CAD94151Q27497418-462CD7DF-A806-4C69-9AF5-1C74D7D27F65Q30490484-48E89D19-20AF-42FD-A2A3-4F040E35889DQ33752301-6021167A-E37D-4F1A-8E7D-5D729582D766Q33806168-7C53C90F-1E3D-409E-9BFB-11035FF38D57Q33907299-5D11455A-266C-4FD7-963D-9543D0838336Q33965859-BFF78A84-EAEF-4E40-887A-A25450E303E3Q34081843-59EC209E-7986-4825-B13C-A14B389F714DQ34207690-AFAE79CE-AE59-41CB-8E6E-0D3B618DCBF8Q34479198-1D18791E-C2A1-438C-879A-3FE561BA2A9FQ34782507-7043BA9F-E933-42E6-9818-8720FCDF9CFBQ34989085-D9814317-2876-4978-AE16-28EA29091AE6Q35172737-A497A58F-893D-4A63-A754-F3EF8DE238E3Q35542905-231097FD-7568-45B0-8932-E3CBA3DD74F6Q35773295-508BE7B7-22C9-45D5-8544-C34BACAF3061Q35792816-395C0F81-C908-41EA-A092-398B694367F3Q35792872-6763C6A2-B060-44C8-866E-2950ECC01772Q36051659-FF529708-D257-4933-8CB8-CE7AA809B36AQ36411205-3BFAED5F-8CEF-4BC3-BAC8-D9B0FE0CBD76Q36421934-3A60C7D9-0D55-4E60-867E-70280B934D1BQ36447357-C4C22DF7-1045-4FCD-B1EC-37AE3DB86E02Q36579964-B96ED023-9CA2-414E-8E97-FC1AE7BB3B66Q36777634-42E8190E-D4B3-49AD-B20A-0A205B7A2F69Q36783489-06F0C9EC-DEC0-4401-BF4B-0A4D4D912CDCQ36810774-6CCC3C94-81A6-4C7D-8F03-95A339F37FF3Q36810813-9F58ECEB-7293-4325-9FC7-E76234C42736Q36930712-764D4685-51F5-41C3-8B0E-DA7C0007AC2CQ37078444-FBB4D39C-D233-4C97-8CCD-CA0626814C51Q37114630-5B04D19C-F52E-4B38-801C-DD34C29572EDQ37114657-1DA3EF83-E73C-477C-B390-CC92EAF86619Q37129644-589CE163-F728-4D89-BABB-380A5F35C022Q37215969-A387B9B9-1713-40ED-B129-C94A45B8CCA1Q37367961-EFF5C57C-01E5-4CD1-869F-C08BBA11489CQ37627314-77EFAAFE-D186-4B41-90A9-1E3C0E623B55Q37676356-21FC4AFC-C210-4B83-9872-C9F69884DB0EQ37811183-DA8C95D2-66BD-4CEE-8028-915F5D4AF50B
P2860
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The Cambridge Pulmonary Hypert ...... s with pulmonary hypertension.
@ast
The Cambridge Pulmonary Hypert ...... s with pulmonary hypertension.
@en
The Cambridge Pulmonary Hypertension Outcome Review
@nl
type
label
The Cambridge Pulmonary Hypert ...... s with pulmonary hypertension.
@ast
The Cambridge Pulmonary Hypert ...... s with pulmonary hypertension.
@en
The Cambridge Pulmonary Hypertension Outcome Review
@nl
prefLabel
The Cambridge Pulmonary Hypert ...... s with pulmonary hypertension.
@ast
The Cambridge Pulmonary Hypert ...... s with pulmonary hypertension.
@en
The Cambridge Pulmonary Hypertension Outcome Review
@nl
P2093
P2860
P921
P1476
The Cambridge Pulmonary Hypert ...... s with pulmonary hypertension.
@en
P2093
J Pepke-Zaba
L C Doward
S P McKenna
P2860
P2888
P304
P356
10.1007/S11136-005-3513-4
P577
2006-02-01T00:00:00Z